Results of interstitial radiotherapy using I-125 seeds in the treatment of prostatic cancer

30 patients with localized adenocarcinoma of the prostate were treated with pelvic lymphadenectomy and I-125 interstitial implantation from 1980 to 1985 (21/30 T3-tumors and 14/30 with poor differentiation). The mean follow-up is 59.5 months (range 18 to 88 months). The crude, progression-free and local progression-free survival rates (Kaplan-Meier) for all patients are 68%, 61% and 71% respectively. But, the progression-free survival is 39% in patients with G3-tumors after five years and only 25% in patients with T3 G3-tumors after four years. The local progression rate was 33% in patients with T3-tumors. We did not observe any late intestinal side-effects, but 11/30 (37%) patients suffered from later urinary flow problems caused mainly by local tumor progression. Therefore, we regard interstitial implantation with I-125-seeds as an alternative treatment to radical prostatectomy in patients with T1, 2 G1, 2-tumors but as insufficient in patients with T3 G3-tumors.